|
|
|
|
Lipin-1, Lipin-2, Lipin-3 Antibodies
The actions of insulin begin with insulin receptor and culminate in changes in the phosphorylation state of a number of downstream targets including phosphatidylinositol 3-OH kinase (PI3-kinase). Activation of PI3-kinase is central to insulin-stimulated phosphorylation in fat cells. In adipocytes, PI3 or the products of PI3 reaction are involved in activation of protein kinase B (PKB), glycogen synthase and phosphorylation of transitional regulators, 4E-BP1, p70s6k and mTOR protein (mammalian target of rapamycin). The kinase activity of mTOR functions in nutrient sensing pathway that maintains a proper balance of aa availability, protein synthesis and cell growth. Most importantly, mTOR controls the phosphorylation of a newly discovered protein Lipin-1, required for normal adipose tissue development and metabolism. Lipin defines a family of nuclear proteins containing at least three members in human and mouse: Lipin-1; Lipin-2 and Lipin-3. All Lipin members contain a nuclear signal seq, a highly conserved amino- (NLIP) and a carboxy-terminal (CLIP) domains. Lipin-1: The human and mouse LPIN-1 genes have been mapped at chromosomes 2p21 and 12, respectively. A region (POMC) on this same chromosome also encodes pro-opiomelanocortin, a locus linked to total adiposity and the levels of plasma protein Leptin. The mouse Lipin-1 is a 140 kDa (891 aa) protein with many potential phosphorylated sites. The overall aa seq of mouse Lipin-1 is over 46 and 49% identical to mouse Lipin-2 and Lipin-3, respectively. The seqs of human and mouse Lipin-1 are over 88% identical. Lpin-1 mRNA is prominently expressed in adipose tissue, skeletal muscle and testis with lower expression in kidney, lung, brain and liver. A Gly84Arg mutation in Lipin-1 alters the protein's subcellular localization from nuclear to cytoplasmic and impairs its activity. The mutation in Lpin-1 gene leads to Lipin-1 deficiency which results in the development of immature adipocytes in fatty liver dystrophy (fld) phenotype in mice and in a group of rare human diseases called lipodystrophy. These phenotypes are characterized by a triglyceride-filled fatty liver, loss of body fat, hypertrigyceridemia, glucose intolerance, insulin resistance, increased susceptibility to atherosclerosis, reduced fertility, reduced plasma Leptin and a progressive neuropathy affecting peripheral nerves in adulthood. Lipin-2: The human and mouse LPIN-2 genes have been mapped at chromosomes 18p and 17, respectively. The Lipin-2 seqs from mouse and human are ~90% identical. The overall aa seq of mouse Lipin-2 (891aa) is ~48% identical to mouse Lipin-1(891aa) and Lipin-3 (848aa). Lipin-3: The human (LPIN3) and mouse Lipin3 genes have been mapped at chromosomes 20q and 2, respectively. The overall aa seq of mouse Lipin-3 (848aa) is 46% and 48% identical to mouse Lipin-1 (891aa, 140 kDa) and Lipin-2 ((891aa), respectively. ADI has produced highly specific rabbit
polyclonal antibodies to Lipin-1, Lipin-2, Lipin-3 which should aid the studies
related to adipose tissue development in the context of obesity, fatty liver
dystrophy, lipodystrophy, insulin resistance and Type 2 diabetes.
* Expected
antibody crossreactivity information is mostly based upon
high (>70%) sequence conservation of antigenic/control peptides in
various species. When antibody crossreactivity has actually been
experimentally confirmed in various species, it will be mentioned in
the appropriate data sheets. | |||||||||||||||||||||||||||||||
|
|